2. Academic Validation
  3. Vascular Cell Adhesion Molecule-1 (VCAM-1) contributes to macular fibrosis in neovascular age-related macular degeneration through modulating macrophage functions

Vascular Cell Adhesion Molecule-1 (VCAM-1) contributes to macular fibrosis in neovascular age-related macular degeneration through modulating macrophage functions

  • Immun Ageing. 2023 Nov 20;20(1):65. doi: 10.1186/s12979-023-00389-x.
Wen Deng 1 2,  Caijiao Yi 2,  Wei Pan 2,  Jian Liu 2,  Jinyan Qi 1 2,  Juan Chen 3,  Zengchao Zhou 3,  Yiqin Duan 3,  Xiangyan Ning 3,  Jun Li 3,  Changhua Ye 1 3,  Zhongping Chen 1 3,  Heping Xu 4 5 6
Affiliations

Affiliations

  • 1 Aier School of Ophthalmology, Central South University, Changsha, China.
  • 2 Aier Institute of Optometry and Vision Science, Changsha, China.
  • 3 Changsha Aier Eye Hospital, Changsha, China.
  • 4 Aier School of Ophthalmology, Central South University, Changsha, China. [email protected].
  • 5 Aier Institute of Optometry and Vision Science, Changsha, China. [email protected].
  • 6 Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, BT9 7BL, UK. [email protected].
PMID: 37985993 DOI: 10.1186/s12979-023-00389-x
Abstract

Background: Neovascular age-related macular degeneration (nAMD) is a major cause of blindness in the elderly. The disease is due to the growth of abnormal blood vessels into the macula, leading to the loss of central vision. Intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors (e.g., anti-VEGF) is the standard of care for nAMD. However, nearly 50% of patients do not respond or respond poorly to the therapy. More importantly, up to 70% of nAMD patients develop macular fibrosis after 10 years of anti-VEGF therapy. The underlying mechanism of nAMD-mediated macular fibrosis is unknown although inflammation is known to play an important role in the development of abnormal macular blood vessels and its progression to fibro-vascular membrane. In this study, we measured the intraocular levels of adhesion molecule VCAM-1, ICAM-1, CD44, CD62L, and CD62P in nAMD patients with and without macular fibrosis and investigated the link between the levels of adhesion molecule and clinical features (e.g., visual improvement, retinal thickness, etc.). We further investigated the effect of VCAM-1 in macrophage function in vitro and the development of subretinal fibrosis in vivo using a two-stage laser-induced protocol.

Results: The aqueous levels of ICAM-1, VCAM-1, CD44, and CD62L were significantly higher in nAMD patients compared to cataract controls. The aqueous level of VCAM-1 (but not other adhesion molecules) was significantly higher in patients with macular fibrosis than those without and the level correlated positively with the retinal thickness. VCAM-1 was highly expressed at the lesion site in the mouse model of subretinal fibrosis. Blocking VCAM-1 or its receptor VLA-4 significantly prevented macrophage infiltration and reduced subretinal fibrosis in vivo. VCAM-1 induced macrophage migration and upregulated the expression of Arg-1, Mmp12 and Il6 but down-regulated the expression of iNOS and Il1b in macrophages.

Conclusions: VCAM-1 may contribute to the development of macular fibrosis in nAMD patients by modulating macrophage functions, including migration and profibrotic polarization.

Keywords

Aqueous humour; Inflammation; Macrophage; Macular fibrosis; Vascular cell adhesion molecule 1.

Figures
Products